Table 1.
Baseline patient characteristics
| Characteristic | No. of patients | Percentage |
|---|---|---|
| Age (years) | ||
| <60 | 9 | 36 |
| ≥60 | 16 | 64 |
| Sex | ||
| Male | 13 | 52 |
| Female | 12 | 48 |
| Performance status | ||
| 0 | 14 | 56 |
| 1 | 9 | 36 |
| 2 | 2 | 8 |
| Diagnosis | ||
| AML | ||
| De novo | 16 | 64 |
| Therapy related/AHD | 8 | 32 |
| CML-AP | 1 | 4 |
| Bone marrow cytogenetics | ||
| t(8;21) | 2 | 8 |
| Normal karyotype | 5 | 20 |
| 11q23, -5, -7, complex | 16 | 64 |
| t(9;22)/other | 2 | 8 |
| Stage of disease | ||
| Primary refractory | 10 | 40 |
| First relapse | 5 | 20 |
| Beyond first relapse | 10 | 40 |
| Prior therapy | ||
| Prior cytarabine | 25 | 100 |
| Prior HiDAC | 20 | 80 |
| Allogeneic stem cell transplant | 5 | 25 |
| Autologous stem cell transplant | 1 | 4 |
| Duration of first CR | ||
| ≥12 months | 5 | 33 |
| <12 months | 10 | 67 |
AHD: antecedent hematologic disorder, CML-AP: chronic myeloid leukemia in the accelerated phase, HiDAC: high dose cytarabine